Phase II randomized study of paclitaxel and paclitaxel plus PSC 833 for advanced breast cancer

被引：0
|
作者：
Spicer, DV
Groshen, S
Doroshow, JH
Synold, T
Gandara, D
Russell, C
Muggia, F
机构：
[1] USC, Norris Canc Ctr, Los Angeles, CA USA
[2] Univ Calif Davis, Davis, CA 95616 USA
[3] NYU, New York, NY USA
来源：
EUROPEAN JOURNAL OF CANCER | 1999年 / 35卷
关键词：
D O I：
10.1016/S0959-8049(99)81689-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1273
引用
收藏
页码：S317 / S317
页数：1
相关论文
共 50 条
  • [1] PHASE-II RANDOMIZED STUDY OF PACLITAXEL VERSUS MITOMYCIN IN ADVANCED BREAST-CANCER
    DIERAS, V
    MARTY, M
    TUBIANA, N
    CORETTE, L
    MORVAN, F
    SERIN, D
    MIGNOT, L
    CHAZARD, M
    GARET, F
    ONETTO, N
    HELLMANN, S
    POUILLART, P
    [J]. SEMINARS IN ONCOLOGY, 1995, 22 (04) : 33 - 39
  • [2] A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines
    Fountzilas, G
    Athanassiades, A
    Giannakakis, T
    Bafaloukos, D
    Karakousis, K
    Dombros, N
    Kosmidis, P
    Skarlos, D
    [J]. EUROPEAN JOURNAL OF CANCER, 1996, 32A (01) : 47 - 51
  • [3] Paclitaxel plus ifosfamide in advanced ovarian cancer - A multicenter phase II study
    Miglietta, L
    Amoroso, D
    Bruzzone, M
    Granetto, C
    Catsafados, E
    Mammoliti, S
    Guarneri, D
    Pedulla, F
    Foglia, G
    Ragni, N
    Martini, MC
    Brema, F
    Addamo, G
    Moraglio, L
    Pastorino, G
    Boccardo, F
    [J]. ONCOLOGY, 1997, 54 (02) : 102 - 107
  • [4] A phase I trial of doxil, paclitaxel and valspodar (PSC 833).
    Advani, R
    Fisher, G
    Lum, B
    Halsey, J
    Sikic, BI
    [J]. CLINICAL CANCER RESEARCH, 2000, 6 : 4504S - 4504S
  • [5] Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: A gynecologic oncology group study
    Fracasso, PM
    Brady, MF
    Moore, DH
    Walker, JL
    Rose, PG
    Letvak, L
    Grogan, TM
    McGuire, WP
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (12) : 2975 - 2982
  • [6] Paclitaxel plus epirubicin in advanced breast cancer
    Conte, PF
    Gennari, A
    Salvadori, B
    Pazzagli, I
    Bengala, C
    [J]. ONCOLOGY-NEW YORK, 1998, 12 (01): : 40 - 44
  • [7] Doxorubicin plus paclitaxel in advanced breast cancer
    Dombernowsky, P
    Boesgaard, M
    Andersen, E
    Jensen, PV
    [J]. SEMINARS IN ONCOLOGY, 1997, 24 (05) : 15 - 18
  • [8] A phase II trial of paclitaxel and epirubicin in advanced breast cancer
    Rischin, D.
    Smith, J.
    Millward, M.
    Lewis, C.
    Boyer, M.
    Richardson, G.
    Toner, G.
    Gurney, H.
    McKendrick, J.
    [J]. BRITISH JOURNAL OF CANCER, 2000, 83 (04) : 438 - 442
  • [9] A phase II trial of paclitaxel and epirubicin in advanced breast cancer
    D Rischin
    J Smith
    M Millward
    C Lewis
    M Boyer
    G Richardson
    G Toner
    H Gurney
    J McKendrick
    [J]. British Journal of Cancer, 2000, 83 : 438 - 442
  • [10] Phase II study of paclitaxel combined with vinorelbine in patients with advanced breast cancer
    Spano, JP
    Bouillet, T
    Boaziz, C
    Piperno-Neumann, S
    Brunel, P
    Hennebelle, F
    Amsalhem, P
    Brunet-Pommeyrol, A
    Kanoui, A
    Morin, F
    Breau, JL
    Morere, JF
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2004, 27 (03): : 317 - 321
12345